Objectives: Late-life psychological symptoms in older adults such as depression and apathy have been increasingly associated with increased risk of cognitive and functional decline. The goal of this study was to conduct a confirmatory factor analysis of the Geriatric Depression Scale (GDS), pooling 3 unique cohorts of older adults to 1) develop a novel measurement model that distinguishes apathy from other domains of depression including dysphoria and cognitive concern and 2) evaluate if the measurement model distinguishes older adult populations with varied risk for cognitive decline.

Methods: We pooled the baseline waves of three older adult cohorts (N=1421). With the aim of partitioning apathy from other constructs that compose the GDS and with a PCA suggesting 3-component solution, we then conducted a confirmatory factor analysis (CFA) using lavaan and less R.

Results: CFA yielded 3 factors: dysphoria, apathy, and cognitive concern. All the dysphoria, apathy, and cognitive concern factors showed acceptable unidimensionality with α=.76, .59, and .54, respectively. The Cognitive Risk Primary Care cohort had significantly higher mean dysphoria, apathy and cognitive concern scales.

Conclusions: This culturally, linguistically, and educationally diverse sample population yielded factors with acceptable reliability and good face validity. This strategy has resulted in a generalizable measurement model to identify people at risk for Alzheimer's disease and related dementia. In particular, the apathy scale score can be used to identify older adults at risk for cognitive and functional decline across research and clinical settings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709455PMC

Publication Analysis

Top Keywords

risk cognitive
16
cognitive concern
16
older adult
12
older adults
12
measurement model
12
dysphoria apathy
12
apathy cognitive
12
cognitive
9
adult populations
8
geriatric depression
8

Similar Publications

Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.

Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.

Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Fundacion Neuropolis, Zaragoza, Zaragoza, Spain.

Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.

View Article and Find Full Text PDF

Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!